---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-036486"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:39:43.890842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics enters $20M equity purchase agreement with Lincoln Park Capital

## Summary
- Lincoln Park committed to buy up to $20M of Indaptus common stock over 36 months (extendable to 48).
- Company controls timing of sales; Lincoln Park cannot require purchases or engage in short selling.
- Indaptus issued 142,450 initial commitment shares; up to 76,220 additional shares may follow after $10M sold.
- Net proceeds will be used for working capital and general corporate purposes.
- Agreement includes standard representations, indemnification, and automatic termination on bankruptcy.

## SEC filing metadata
- accession: 0001493152-22-036486
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/0001493152-22-036486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-036486
- JSON: https://secwatch.observer/filing/0001493152-22-036486.json
- Plain text: https://secwatch.observer/filing/0001493152-22-036486.txt

## Key facts
- Material Agreements
  Indaptus Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at Up to $20,000,000 (effective 2022-12-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Value: Up to $20,000,000
  - Effective: 2022-12-22
  source text: On December, 22, 2022, Indaptus Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $20.0 million of the Company’s common stock, $0.01 par value per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/0001493152-22-036486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.